Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
The February shutdown of the largest formula factory in the country led to supply problems. → Read More
The action by the Food and Drug Administration means the agency has completed the same rigorous, time-consuming review of Moderna’s shot as dozens of other long-established vaccines. → Read More
The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they’ve used to fight COVID-19. → Read More
The Food and Drug Administration posted its analysis of the pill ahead of a public meeting next week where academic and other experts will weigh in on its safety and effectiveness. → Read More
If the CDC agrees, tens of millions more Americans could have three doses of protection ahead of the new year. Anyone who got the one-dose Johnson & Johnson vaccine can already get a booster. → Read More
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months. → Read More
Details of the study were posted online Friday as U.S. regulators consider opening vaccinations to youngsters 5 to 11. → Read More
The FDA’s Doran Fink previewed “some announcements later today,” which were expected to include allowing the mixing and matching of COVID-19 booster doses among the three U.S. manufacturers — Pfizer, Moderna and J&J. Fink appeared at a meeting of vaccine experts convened by the Centers for Disease Control and Prevention, who are expected to take up the FDA decisions and make their own… → Read More
J&J said it filed a request with the FDA to authorize boosters for people who previously received the company’s one-shot vaccine. While company said it submitted data on several different booster intervals, ranging from two to six months, it did not formally recommend one to regulators. → Read More
The Food and Drug Administration said the change is intended to address confusion among physicians and patients about who should get the drug, which has faced an intense public backlash since its approval last month. → Read More
Government health experts are urging approval of a treatment for children with life-threatening peanut allergies. → Read More
U.S. health regulators have approved a treatment for seizures that is the first prescription drug made from marijuana. → Read More
After more than a year of bold promises, President Donald Trump is unveiling his plans for reducing drug prices. → Read More